Wedbush Forecasts Strong Price Appreciation for Janux Therapeutics (NASDAQ:JANX) Stock

Janux Therapeutics (NASDAQ:JANX) had its price objective upped by stock analysts at Wedbush from $36.00 to $40.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Wedbush‘s price objective would suggest a potential upside of 126.89% from the company’s previous close.

Several other analysts also recently commented on JANX. Wolfe Research upgraded Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 target price for the company in a research note on Monday, August 24th. Guggenheim dropped their price target on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Barclays increased their price target on Janux Therapeutics from $14.00 to $15.00 and gave the stock an “underweight” rating in a report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a report on Friday, October 16th. Finally, TD Cowen raised Janux Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Janux Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $36.92.

Janux Therapeutics Trading Up 9.8%

NASDAQ:JANX opened at $17.63 on Friday. Janux Therapeutics has a 12 month low of $12.12 and a 12 month high of $35.34. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -11.09 and a beta of 2.44. The firm has a fifty day simple moving average of $17.49 and a two-hundred day simple moving average of $15.42.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.13. The company had revenue of $9.29 million for the quarter, compared to analyst estimates of $8.03 million. Equities analysts predict that Janux Therapeutics will post -1.70 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in JANX. Diversified Trust Co grew its stake in Janux Therapeutics by 3.5% in the 3rd quarter. Diversified Trust Co now owns 17,429 shares of the company’s stock valued at $301,000 after purchasing an additional 588 shares during the period. GAMMA Investing LLC raised its stake in shares of Janux Therapeutics by 67.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,642 shares of the company’s stock worth $28,000 after purchasing an additional 661 shares during the period. Versant Capital Management Inc raised its stake in shares of Janux Therapeutics by 42.8% during the 2nd quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock worth $40,000 after purchasing an additional 784 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in shares of Janux Therapeutics by 8.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 12,350 shares of the company’s stock worth $213,000 after purchasing an additional 1,000 shares during the period. Finally, Quantinno Capital Management LP boosted its holdings in shares of Janux Therapeutics by 7.6% in the 1st quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock worth $362,000 after buying an additional 1,846 shares during the last quarter. 75.39% of the stock is owned by institutional investors.

Key Stories Impacting Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $40 from $36 and reiterated its outperform rating, implying substantial upside from the cited $17.63 share price. Wedbush raises Janux price target
• Positive Sentiment: Truist raised its target to $27 from $26 and maintained a buy rating, signaling continued confidence in JANX. Truist analyst recommendations
• Positive Sentiment: Janux reported a third-quarter loss of $0.34 per share, narrower than analysts’ expected loss of $0.45–$0.47. Revenue of $9.29 million also exceeded the $8.03 million estimate. The results beat expectations, although the company remained loss-making. Janux third-quarter 2026 results
• Neutral Sentiment: Janux said it dosed the first patient in the Phase 1 study of JANX013 in combination with JANX007, marking progress in its clinical pipeline; the update does not establish how the treatment will perform. Janux business highlights
• Negative Sentiment: Barclays raised its target only to $15 from $14 but kept an underweight rating, placing its target below the cited share price and underscoring a bearish view that contrasts with other analysts. Barclays analyst recommendations

About Janux Therapeutics

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.